Article Text

Download PDFPDF
The process of producing recommendations for rheumatic diseases: what is evidence?
  1. J Zochling1,
  2. D van der Heijde2,
  3. M Dougados3,
  4. J Braun1
  1. 1Rheumazentrum-Ruhrgebiet, Herne, Germany
  2. 2Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht and Caphri Research Institute, The Netherlands
  3. 3Service de Rheumatologie B, Hospital Cochin, Paris, France
  1. Correspondence to:
    Professor J Braun
    Rheumazentrum-Ruhrgebiet, Landgrafenstrasse 15, 44652 Herne, Germany; J.Braun{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The EULAR Standing Committee for International clinical Studies Including Therapeutics (ESCISIT) encourages the production of international evidence based recommendations for the management of rheumatic diseases. This has already led to published recommendations in osteoarthritis,1,2 and ankylosing spondylitis (AS),3 and recommendations for other disease states, including early rheumatoid arthritis and gout, have recently been completed. As a guide to the process for developing recommendations, standard operating procedures (SOPs) have been published,4 which include recommendations for the formation of a steering group, defining a target population, and the use of research evidence.

Although the SOP is generally straight­forward, several problems came up during the development of the recommen­dations for AS3 about wording and interpretation, which led to the decision to write this …

View Full Text


  • Published Online First 24 November 2006